InflaRx (IFRX) to Release Quarterly Earnings on Wednesday

InflaRx (NASDAQ:IFRX) will issue its quarterly earnings data before the market opens on Wednesday, May 8th. Analysts expect the company to announce earnings of ($0.24) per share for the quarter.

InflaRx (NASDAQ:IFRX) last posted its quarterly earnings data on Thursday, March 21st. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.10). On average, analysts expect InflaRx to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

InflaRx Stock Performance

Shares of NASDAQ IFRX opened at $1.40 on Monday. The firm has a market cap of $82.43 million, a PE ratio of -1.60 and a beta of 1.26. InflaRx has a one year low of $1.14 and a one year high of $5.20. The firm has a fifty day moving average of $1.52 and a 200 day moving average of $1.55.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $8.00 price target on shares of InflaRx in a research report on Friday, March 22nd.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.